Study design (if review, criteria of inclusion for studies)
The study was performed as part of a trial comparing daily rhDNase with alternate day rhDNase and hypertonic saline in CF.
Interventions
daily rhDNase with alternate day rhDNase and hypertonic saline
Outcome measures
The primary outcome was FEV(1). Secondary outcomes were forced vital capacity (FVC), forced expiratory flow at 25-75% of forced vital capacity (FEF(25-75)), number of pulmonary exacerbations, weight gain, quality of life (QOL), and exercise tolerance. The usefulness of each secondary outcome was investigated by assessing if the change in that outcome over the treatment period could be predicted from the primary outcome
Main results
Change in FEV(1) correlated with changes in FVC (r(2)=0.76, P=0.001), FEF(25-75) (r(2)=0.64, P=0.001), weight (r(2)=0.08, P=0.001), and change in oxygen saturation with exercise (r(2)=0.08, P=0.001). However, it did not correlate with changes in visual analogue score (VAS) with exercise, QOL, nor with the occurrence of pulmonary exacerbations.
Authors' conclusions
Only the outcomes QOL and VAS with exercise actually provided additional information to FEV(1) in this study.